These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 15602099)
21. Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease. Mizukami K; Tanaka Y; Asada T Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1342-6. PubMed ID: 16603301 [TBL] [Abstract][Full Text] [Related]
22. Controlled comparison of milnacipran and fluoxetine in major depression. Ansseau M; Papart P; Troisfontaines B; Bartholomé F; Bataille M; Charles G; Schittecatte M; Darimont P; Devoitille JM; De Wilde J Psychopharmacology (Berl); 1994 Feb; 114(1):131-7. PubMed ID: 7846195 [TBL] [Abstract][Full Text] [Related]
23. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Saxe PA; Arnold LM; Palmer RH; Gendreau RM; Chen W Curr Med Res Opin; 2012 May; 28(5):815-21. PubMed ID: 22429066 [TBL] [Abstract][Full Text] [Related]
24. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Matthey A; Cedraschi C; Piguet V; Besson M; Chabert J; Daali Y; Courvoisier D; Montagne A; Dayer P; Desmeules JA Pain Physician; 2013; 16(5):E553-62. PubMed ID: 24077206 [TBL] [Abstract][Full Text] [Related]
25. The evaluation of analgesic effects of milnacipran and sertraline in tail-flick test. Kesim M; Yanik MN; Kadioglu M; Pepeoglu D; Erkoseoglu I; Kalyoncu NI; Yaris E Bratisl Lek Listy; 2014; 115(1):3-6. PubMed ID: 24471894 [TBL] [Abstract][Full Text] [Related]
26. Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness. Horii A; Imai T; Kitahara T; Uno A; Morita Y; Takahashi K; Inohara H J Vestib Res; 2016 Jul; 26(3):335-40. PubMed ID: 27392838 [TBL] [Abstract][Full Text] [Related]
27. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders. Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843 [TBL] [Abstract][Full Text] [Related]
28. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program. Arnold LM; Bateman L; Palmer RH; Lin Y Pediatr Rheumatol Online J; 2015 Jun; 13():27. PubMed ID: 26112278 [TBL] [Abstract][Full Text] [Related]
29. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials. Mease PJ; Palmer RH; Wang Y J Clin Rheumatol; 2014 Jun; 20(4):195-202. PubMed ID: 24847745 [TBL] [Abstract][Full Text] [Related]
30. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency. Isaac MT; Isaac MB; Gallo F; Tournoux A Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018 [TBL] [Abstract][Full Text] [Related]
31. Effectiveness of milnacipran for a patient with pain disorder and long QT syndrome. Ikawa M; Yamada K Clin Neuropharmacol; 2010 May; 33(3):163-4. PubMed ID: 20173629 [TBL] [Abstract][Full Text] [Related]
32. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Ansseau M; von Frenckell R; Mertens C; de Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P; Dejaiffe G Psychopharmacology (Berl); 1989; 98(2):163-8. PubMed ID: 2569214 [TBL] [Abstract][Full Text] [Related]
33. [Acute prostatism associated with milnacipran therapy: a case report]. Akpinar A Turk Psikiyatri Derg; 2009; 20(4):403-5. PubMed ID: 20013433 [TBL] [Abstract][Full Text] [Related]
34. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. Van Amerongen AP; Ferrey G; Tournoux A J Affect Disord; 2002 Oct; 72(1):21-31. PubMed ID: 12204314 [TBL] [Abstract][Full Text] [Related]
35. No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery. Okkerse P; Alvarez-Jimenez R; Hay JL; Tehim A; Kumar R; de Kam ML; Groeneveld GJ Eur J Pain; 2017 Mar; 21(3):494-506. PubMed ID: 27651026 [TBL] [Abstract][Full Text] [Related]
36. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. Lopez-Ibor JJ; Conesa A; Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743 [TBL] [Abstract][Full Text] [Related]
37. Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study. Trugman JM; Palmer RH; Ma Y Curr Med Res Opin; 2014 Apr; 30(4):589-97. PubMed ID: 24188161 [TBL] [Abstract][Full Text] [Related]
38. Monoamine-dependent, opioid-independent antihypersensitivity effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a postoperative pain model in rats. Obata H; Kimura M; Nakajima K; Tobe M; Nishikawa K; Saito S J Pharmacol Exp Ther; 2010 Sep; 334(3):1059-65. PubMed ID: 20558774 [TBL] [Abstract][Full Text] [Related]
39. A case of severe parkinsonism associated with short-term treatment with milnacipran. Muraoka T; Oku E; Sugataka K; Yamada S Clin Neuropharmacol; 2008; 31(5):299-300. PubMed ID: 18836350 [TBL] [Abstract][Full Text] [Related]
40. Occurrence of milnacipran-associated morbilliform rash and serotonin toxicity. Huskey AM; Thomas CC; Waddell JA Ann Pharmacother; 2013; 47(7-8):e32. PubMed ID: 23837199 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]